MedTrace Logo

A Multi-modal Integrating Imaging and Cell-free DNA Methylation in Lung Cancer Early Detection (CMe-Lung): a Multi-center, Observational Study

NCT07375979 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 14300

Last updated 2026-01-29

No results posted yet for this study

Summary

This study is a multi-center, observational study aiming to develop an early screening multi-model for detecting lung cancer signals through the integration of imaging (non-contrast CT) and blood testing (cfDNA methylation).

Conditions

Sponsors & Collaborators

  • Shanghai Chest Hospital

    collaborator OTHER

  • Liaoning Cancer Hospital & Institute

    collaborator OTHER

  • The First Affiliated Hospital of Zhengzhou University

    collaborator OTHER

  • Yunnan Cancer Hospital

    collaborator OTHER

  • Shijiazhuang People's Hospital

    collaborator OTHER

  • The First Hospital of Jilin University

    collaborator OTHER

  • Shanghai Pulmonary Hospital, Shanghai, China

    lead OTHER

Eligibility

Min Age
40 Years
Max Age
74 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-02-05
Primary Completion
2026-03-01
Completion
2026-09-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07375979 on ClinicalTrials.gov